Background: Total arterial revascularization (TAR) for coronary artery bypass grafting (CABG) is increasingly recognized for its potential to improve long-term graft patency and patient survival compared to venous conduits. Despite its biologic advantages, TAR adoption remains limited due to the technical demands of the procedure and concerns regarding sternal wound complications. Objective: To evaluate the early clinical and angiographic outcomes of total arterial coronary artery bypass grafting (TAR-CABG) for complete myocardial revascularization. Methods: This retrospective observational study included 35 consecutive adult patients who underwent isolated elective or urgent TAR-CABG at a single tertiary-care center between April 2018 and December 2025. Perioperative data and one-year computed tomography (CT) coronary angiography results were analyzed. Results: The cohort was predominantly male (88.6%) with a mean age of 52.6 ± 9.0 years. Revascularization was performed off-pump in 30 patients (85.7%). Left internal mammary artery (LIMA) utilization was universal, and bilateral internal mammary artery (BIMA) utilization was achieved in 71.4% of patients. Mean left ventricular ejection fraction (LVEF) significantly improved from 49.2 ± 11.1% preoperatively to 54.3 ± 8.9% on postoperative day 3 (paired P=0.018). Perioperative mortality was 5.7%, and wound dehiscence occurred in 17.1% of patients. One-year CT angiography demonstrated 100% patency for both LIMA and right internal mammary artery (RIMA) grafts, and 60% patency for assessed radial artery grafts, yielding an overall arterial graft patency of 96.7%. Conclusion: Total arterial revascularization, predominantly performed off-pump, is technically feasible and yields excellent early internal mammary artery patency alongside significant early ventricular recovery. However, the rates of sternal wound complications and lower radial artery patency underscore the need for meticulous conduit harvesting and careful target-vessel selection.
Coronary artery bypass grafting (CABG) has been the procedure of choice for the past four decades for patients with complex left main and multivessel disease, offering significant survival benefits alongside acceptable postoperative morbidity and mortality [1]. With advancements in perioperative management and surgical techniques, in-hospital mortality has declined steadily. While short-term results are undisputed, long-term outcomes have remained a subject of ongoing discussion [2].
The first successful human CABG procedure was performed in 1960 by Dr. Robert Goetz, who anastomosed the right internal mammary artery (RIMA) to the right coronary artery [3]. In 1968, Dr. George Green performed the first left internal mammary artery (LIMA) to left anterior descending (LAD) anastomosis, establishing what would become the gold standard in coronary surgery [4]. Concurrently, Favaloro pioneered the use of the saphenous vein graft (SVG), utilizing it in conjunction with the internal mammary artery via end-to-side anastomosis [5].
During the early 1980s, patients receiving LIMA grafts demonstrated superior survival compared to those exclusively receiving SVGs, which showed an increased propensity for accelerated atherosclerosis [6, 7]. Following the success of the LIMA, surgeons hypothesized that utilizing other arterial conduits—such as the RIMA, radial artery, and gastroepiploic artery—alongside the LIMA would be superior to SVG utilization in terms of mitigating myocardial infarction, all-cause mortality, and the need for repeat revascularization [8, 9]. Despite these biologic advantages, approximately 95% of surgeons worldwide continue to perform LIMA-to-LAD grafting while relying on SVGs for the right and circumflex territories [10].
For total arterial revascularization (TAR), bilateral internal mammary artery (BIMA) grafting has demonstrated superior patency rates and survival compared to non-TAR approaches, though it is frequently associated with complications such as deep sternal wound infections. This risk profile elevated the radial artery as a preferred second-choice conduit, offering robust patency rates, improved survival, and reduced major adverse cardiac events compared with RIMA and SVG usage [11, 12]. Consequently, the choice of conduit remains a subject of global debate. The purpose of this study is to evaluate the early outcomes of total arterial CABG based on our institutional experience.
Study Design and Population
This retrospective observational study included consecutive adults undergoing total arterial coronary artery bypass grafting (TAR-CABG) at a single tertiary-care cardiac surgery center (Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi) between April 2018 and December 2025. The study was approved by the Institutional Ethics Committee, and the requirement for individual patient consent was waived due to the retrospective nature of the study.
Inclusion and Exclusion Criteria
Comprised age ≥18 years, patients undergoing isolated elective or urgent CABG, the exclusive use of arterial conduits for complete myocardial revascularization, and the availability of complete perioperative records. Patients were excluded if they required concomitant valve surgery, congenital cardiac procedures, aortic surgery, had a history of previous CABG, or had incomplete medical records.
Data Collection Demographic, clinical, echocardiographic, operative, and postoperative data were retrospectively extracted from institutional databases, operative logs, hospital charts, and follow-up documentation. Baseline variables included age, sex, body mass index, diabetes status, hypertension, smoking history, hypothyroidism, LVEF, and regional wall-motion abnormalities (RWMA). Operative variables included the type of conduit, harvesting technique, operative strategy (on-pump vs. off-pump), number of diseased vessels and grafts, target vessels, adjunct coronary endarterectomy, and cardiopulmonary bypass (CPB) duration.
Echocardiographic Assessment
Transthoracic echocardiography was performed preoperatively and approximately 3 days postoperatively. LVEF and RWMA were recorded. For patients with paired measurements, the change in LVEF was calculated to assess early functional recovery. Missing data were excluded from paired analyses.
CT Angiographic Assessment
CT coronary angiography was performed one year postoperatively for all available patients, regardless of symptom status, to assess and record graft patency.
Surgical Technique
All procedures were performed through a standard median sternotomy using exclusively arterial conduits. The LIMA was routinely utilized for LAD revascularization, while the RIMA and/or radial artery were deployed based on individual coronary anatomy and the severity of lesions in the right and left systems. Internal mammary arteries were harvested using either pedicled or skeletonized techniques, with skeletonization favored in diabetic patients. Sequential and composite arterial grafting was performed when appropriate. CABG was executed either off-pump or on-pump, dictated by patient characteristics, coronary anatomy, and surgeon preference.
Early Outcomes
outcomes assessed included postoperative LVEF, RWMA, intensive care unit (ICU) and total hospital length of stay, wound dehiscence, re-exploration, postoperative atrial fibrillation, intra-aortic balloon pump (IABP) requirement, and perioperative mortality (defined as death during the index hospitalization). One-year graft patency was evaluated at the graft level via CT coronary angiography, classifying LIMA, RIMA, and radial artery grafts as either patent or occluded. Patency analysis included only those conduits documented as utilized during the index operation and successfully imaged at one year.
Statistical Analysis
Continuous variables are expressed as mean ± standard deviation (SD) or median with interquartile range (IQR), as appropriate. Categorical variables are reported as frequencies and percentages. Preoperative and postoperative LVEF values were compared using a paired Student's t-test for patients with available measurements at both time points. One-year graft patency was calculated at the graft level, with 95% confidence intervals estimated using the Wilson method. Given the relatively small sample size—which reflects the strict selection criteria during the early adoption phase of this TAR protocol—analyses were predominantly descriptive, and multivariable modeling was not performed. A two-sided P value <0.05 was considered statistically significant.
Patient Characteristics A total of 35 patients underwent total arterial CABG during the study period. The mean age was 52.6 ± 9.0 years, and the mean body mass index was 24.1 ± 3.5 kg/m². The cohort was predominantly male (31/35, 88.6%). Comorbidities included diabetes mellitus in 15 patients (42.9%), hypertension in 13 (37.1%), current or previous smoking in 5 (14.3%), and hypothyroidism in 4 (11.4%). The mean preoperative LVEF was 49.2 ± 11.1%, with RWMA documented in 19 patients (54.3%). Preoperative LVEF data were available for 34 patients.
Operative Characteristics and Grafting Configuration
Operative variables are summarized in Table 2. Revascularization was successfully performed off-pump in 30 patients (85.7%). Five patients (14.3%) underwent on-pump CABG, with CPB durations ranging between 140 and 167 minutes. The mean number of diseased coronary arteries was 2.8 ± 0.5, and the mean number of distal anastomoses performed was 2.6 ± 1.2 per patient. In total, 14 patients (40.0%) received three grafts, 7 (20.0%) received four grafts, 1 (2.9%) received five grafts, 4 (11.4%) received two grafts, and 9 (25.7%) received a single graft. In the 9 patients with multivessel disease who received a single graft, non-LAD coronary targets were found intraoperatively to be diminutive (<1.0 mm), diffusely diseased, or severely calcified without an adequate distal landing zone, prompting a clinical decision to forgo secondary grafting. Coronary endarterectomy was adjunctively performed in 7 patients (20.0%).
LIMA utilization was universal (35/35, 100%), harvested as a pedicled conduit in 29 patients (82.9%) and skeletonized in 6 (17.1%). The RIMA was utilized in 25 patients (71.4%), comprising 19 pedicled (54.3%) and 6 skeletonized (17.1%) grafts. A left radial artery was deployed in 5 patients (14.3%). Consequently, BIMA utilization was achieved in 71.4% of the cohort. Target vessels grafted included the LAD in all 35 patients (100%), obtuse marginal branches in 20 (57.1%), posterior descending artery in 14 (40.0%), first diagonal branch in 10 (28.6%), right coronary artery trunk in 7 (20.0%), and ramus intermedius in 3 (8.6%).
Early Postoperative Outcomes
There was a significant early improvement in ventricular systolic function following surgery. Among the 34 patients with paired preoperative and postoperative measurements, mean LVEF increased from 49.2 ± 11.1% preoperatively to 54.3 ± 8.9% on postoperative day 3, representing a mean absolute increase of 5.0 ± 11.7 percentage points (paired P=0.018). Postoperative RWMA was documented in only 2 patients (5.7%).
The mean ICU length of stay was 4.5 ± 1.7 days (median 4 days, IQR 4–5), and the mean hospital stay was 14.9 ± 7.6 days (median 13 days, IQR 11–16.5). Wound dehiscence occurred in 6 patients (17.1%). One patient (2.9%) required re-exploration for high drain output. No patient developed postoperative atrial fibrillation, and none required IABP support. There were 2 perioperative deaths (5.7%) during the index hospitalization.
One-Year CT Angiographic Graft Patency
One-year CT coronary angiography demonstrated excellent patency of the assessed internal mammary artery grafts. All assessed LIMA grafts were patent (33/33, 100%), as were all assessed RIMA grafts (23/23, 100%). Among the five assessed left radial artery grafts, 3 (60.0%) remained patent and 2 (40.0%) were occluded. Overall, 59 of 61 assessed arterial grafts were patent (96.7%), with only 2 grafts occluded. Patency analysis was restricted to conduits documented as used and subsequently assessed at one year. All 33 survivors had documented LIMA assessment; RIMA assessment was available for 23 patients, and left radial artery assessment was available for 5 patients.
Graft patency depends on multiple variables, including the location, size, and severity of the target lesion, the types of conduits used, runoff territory, surgical technique, surgeon experience, and postoperative medical management [13]. The well-recognized decline in SVG patency over time, contrasted against the sustained durability of arterial grafts, has heavily encouraged the use of multiple arterial conduits to achieve complete coronary revascularization [6, 14]. Currently, TAR is the preferred procedural strategy in patients under 70 years of age with a life expectancy greater than five years. Beyond providing superior patency, arterial grafts possess biological properties that help protect native coronary arteries against the further progression of atherosclerotic disease [15].
Muneretto et al. demonstrated that TAR was associated with increased freedom from major adverse cardiac and cerebrovascular events (MACCE), recurrent angina, graft occlusion, and late death in patients over 50 years of age, with these benefits extending to elderly patients over 70 years of age [16-18]. Nicolini et al. identified chronic kidney disease (CKD), male sex, increasing age, peripheral arterial disease (PAD), and single internal mammary artery usage as predictors for late death, noting no significant difference between males and females regarding the efficacy of total arterial grafts [19]. Furthermore, Guru et al. suggested substantial mortality and morbidity benefits for multiple arterial grafts compared to single arterial grafts [20]. Locker et al. demonstrated a 35% survival benefit during long-term follow-up with multiple arterial grafting, a benefit similarly observed in females, diabetics, and elderly patients facing highly complex coronary disease [21]. Extensive contemporary analyses continue to confirm a significant reduction in all-cause mortality associated with TAR [22-25].
Desai et al. demonstrated a significantly lower rate of angiographic occlusion with radial artery grafts compared to SVGs at one year, emphasizing the critical importance of grafting the radial artery only to coronary targets with severe native stenosis. A patient-level pooled analysis of randomized trials involving over 1,000 patients demonstrated lower rates of death, myocardial infarction, or repeat revascularization, alongside substantially lower graft occlusion rates with radial arteries compared with SVGs over approximately 5 years [26].
The Arterial Revascularization Trial (ART), which randomized over 3,000 patients to bilateral versus single internal thoracic artery grafting, reported no significant difference in all-cause mortality at 10 years (20.3% vs 21.2%; P=0.62) [27]. However, sternal wound complications were notably more frequent with bilateral grafting (3.5% vs 1.9%) [27]. Thus, while arterial grafting offers vital biological and patency advantages, conduit selection must remain individualized according to patient characteristics, target-vessel anatomy, diabetic status, sternal infection risk, and surgical expertise.
The contemporary shift toward TAR is further supported by several comprehensive analyses published over the last three years. A 2022 critical evaluation by Gaudino et al. highlighted that despite a steeper surgical learning curve, multiple arterial grafting confers a definitive biologic advantage in preventing late graft failure compared to venous conduits, particularly in patients with multivessel disease [30]. Furthermore, recent large-scale propensity-matched studies, such as the 2023 analysis by Ohira and colleagues, have reaffirmed that TAR significantly improves long-term survival and freedom from major adverse cardiovascular events (MACE), even across higher-risk demographic subgroups [31]. El-Andari et al. (2022) also emphasized that while the technical demands of TAR are substantial—especially when executed without cardiopulmonary bypass—the strategic integration of BIMA and radial artery conduits optimizes target-vessel matching and minimizes aortic manipulation [32]. This strongly aligns with our institutional approach, where off-pump TAR was achieved in 85.7% of cases, prioritizing both superior long-term conduit patency and reduced perioperative risk.
An important finding in our early institutional experience was the occurrence of wound-related morbidity, with wound dehiscence presenting in 17.1% of patients. Although the majority of these complications were not associated with major deep sternal infections requiring extensive debridement or sternal plating, this rate highlights one of the principal challenges associated with extensive arterial conduit harvesting, particularly when BIMAs are utilized.
Another defining feature of our experience was the predominant use of off-pump CABG (85.7%). The mean number of diseased vessels was 2.8 ± 0.5, and the mean number of grafts was 2.6 ± 1.2, indicating that our arterial strategy was successfully applied in patients with complex multivessel disease. Three or more grafts were performed in nearly 63% of the cohort, and adjunct coronary endarterectomy was required in 20% of patients. The combination of multiple arterial conduits, multivessel disease, and an off-pump approach represents a technically demanding strategy, reflecting the maturation of a comprehensive arterial revascularization program rather than the simple substitution of an SVG.
Crucially, we observed a statistically significant improvement in left ventricular systolic function following revascularization (mean absolute LVEF increase of 5.0 ± 11.7 percentage points by postoperative day 3; P=0.018). Furthermore, one-year CT angiography demonstrated exceptional internal mammary artery patency (100% for both LIMA and RIMA). Conversely, only 3 of 5 assessed radial artery grafts remained patent. This 60% patency rate likely reflects the heightened physiological vulnerability of muscular radial conduits to competitive flow and vasospasm. Because only five radial grafts were placed, individual anatomic variables, runoff quality, and patient compliance with postoperative calcium channel blockers exerted an outsized impact on the calculated rate. Long-term randomized data generally supports the radial artery as a highly effective second conduit when deployed appropriately [28, 29]. Our localized 60% patency observation warrants further evaluation, as our current dataset cannot definitively isolate whether these occlusions were driven by target-vessel stenosis severity, competitive flow, conduit spasm, or technical factors.
Limitations
This study carries several limitations that must be acknowledged. First, the small cohort of 35 patients restricts statistical power and precision, precluding complex multivariable modeling. Second, as a single-center observational study representing an early institutional experience, the outcomes are inherently influenced by the surgical learning curve associated with adopting a TAR protocol. Third, the study lacks a contemporaneous conventional CABG control group, preventing direct statistical comparison with standard LIMA-plus-SVG revascularization at our centre. Finally, the small number of radial artery grafts assessed at one year makes the observed 60% patency estimate highly vulnerable to random variation.
Our early institutional experience demonstrates that total arterial coronary artery bypass grafting is a technically feasible and highly effective strategy for multivessel coronary revascularization in appropriately selected patients. LIMA utilization was universal, BIMA grafting was achieved in the majority of patients, and most procedures were successfully completed off-pump. The approach yielded significant early improvements in ventricular function. One-year CT angiography confirmed excellent patency of the assessed internal mammary artery grafts. These findings strongly support the continued utilization and refinement of total arterial revascularization programs. Future efforts must emphasize meticulous conduit harvesting to mitigate sternal wound complications, strict anatomical criteria for radial artery target selection, and the systemic, long-term tracking of graft patency and clinical outcomes.
1. Ghali WA, Quan H, Shrive FM, Hirsch GM. Outcomes after coronary artery bypass graft surgery in Canada: 1992/93 to 2000/01. Can J Cardiol. 2003;19(7):774-781.
2. Abramov D, Tamariz MG, Fremes SE, et al. Trends in coronary artery bypass surgery results: a recent, 9-year study. Ann Thorac Surg. 2000;70(1):84-90.
3. Olearchyk AS. Vasilii I. Kolesov: a pioneer of coronary revascularization by internal mammary-coronary artery grafting. J Thorac Cardiovasc Surg. 1988;96(1):13-18.
4. Melly L, Torregrossa G, Lee T, Jansens JL, Puskas JD. Fifty years of coronary artery bypass grafting. J Thorac Dis. 2018;10(3):1960-1967.
5. Ghandakly EC, Iacona GM, Bakaeen FG. Coronary artery surgery: past, present, and future. Rambam Maimonides Med J. 2024;15(1):e0001.
6. Lytle BW, Loop FD, Cosgrove DM, et al. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg. 1985;89(2):248-258.
7. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med. 1986;314(1):1-6.
8. Khan A, Gupta V, Choudhary SK, et al. Radial artery in CABG: could the early results be comparable to internal mammary artery graft? Ann Thorac Surg. 1999;67(6):1631-1636.
9. Cohen G, Tamariz MG, Sever JY, et al. The radial artery versus the saphenous vein graft in contemporary CABG: a case-matched study. Ann Thorac Surg. 2001;71(1):180-185.
10. Royse A, Pawanis Z, Canty D, et al. The effect on survival from the use of a saphenous vein graft during coronary bypass surgery: a large cohort study. Eur J Cardiothorac Surg. 2018;54(6):1093-1100.
11. Klima U, Elsebay AA, Gantri MR, et al. Computerized tomographic angiography in patients having eSVS Mesh® supported coronary saphenous vein grafts: intermediate term results. J Cardiothorac Surg. 2014;9:126.
12. Gaudino M, Lorusso R, Rahouma M, et al. Radial artery versus right internal thoracic artery versus saphenous vein as the second conduit for coronary artery bypass surgery: a network meta-analysis of clinical outcomes. J Am Heart Assoc. 2019;8(24):e010839.
13. Bradshaw PJ, Jamrozik K, Gilfillan I, Thompson PL. Preventing recurrent events long term after coronary artery bypass graft: Suboptimal use of medications in a population study. Am Heart J. 2004;147(6):1047-1053.
14. Pick AW, Orszulak TA, Anderson BJ, Schaff HV. Single versus bilateral internal mammary artery grafts: 10-year outcome analysis. Ann Thorac Surg. 1997;64(3):599-605.
15. Dimitrova KR, Hoffman DM, Geller CM, et al. Arterial grafts protect the native coronary vessels from atherosclerotic disease progression. Ann Thorac Surg. 2012;94(2):475-478.
16. Muneretto C, Bisleri G, Negri A, et al. Left internal thoracic artery-radial artery composite grafts as the technique of choice for myocardial revascularization in elderly patients: a prospective randomized evaluation. J Thorac Cardiovasc Surg. 2004;127(1):179-184.
17. Muneretto C, Bisleri G, Negri A, et al. Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery. Circulation. 2003;108 Suppl 1:II29-II33.
18. Muneretto C, Negri A, Manfredi J, et al. Safety and usefulness of composite grafts for total arterial myocardial revascularization: a prospective randomized evaluation. J Thorac Cardiovasc Surg. 2003;125(4):826-835.
19. Nicolini F, Vezzani A, Fortuna D, et al. Gender differences in outcomes following isolated coronary artery bypass grafting: Long-term results. J Cardiothorac Surg. 2016;11(1):144.
20. Guru V, Fremes SE, Tu JV. How many arterial grafts are enough? A population-based study of midterm outcomes. J Thorac Cardiovasc Surg. 2006;131(5):1021-1028.
21. Locker C, Schaff HV, Dearani JA, et al. Multiple arterial grafts improve late survival of patients undergoing coronary artery bypass graft surgery: analysis of 8622 patients with multivessel disease. Circulation. 2012;126(9):1023-1030.
22. Ren J, Royse C, Srivastav N, Lu O, Royse A. Long-term survival of multiple versus single arterial coronary bypass grafting in elderly patients. J Clin Med. 2023;12(7):2594.
23. Ren J, Royse C, Tian DH, Gupta A, Royse A. Survival of multiple arterial grafting in diabetic populations: a 20-year national experience. Eur J Cardiothorac Surg. 2023;63(4):ezad091.
24. Ren J, Bowyer A, Tian DH, et al. Multiple arterial vs. single arterial coronary artery bypass grafting: sex-related differences in outcomes. Eur Heart J. 2024;45(27):2536-2544.
25. Yanagawa B, Verma S, Mazine A, et al. Impact of total arterial revascularization on long term survival: a systematic review and meta-analysis of 130,305 patients. Int J Cardiol. 2017;233:29-36.
26. Desai ND, Cohen EA, Naylor CD, Fremes SE; Radial Artery Patency Study Investigators. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. N Engl J Med. 2004;351(22):2302-2309.
27. Taggart DP, Benedetto U, Gerry S, et al; Arterial Revascularization Trial Investigators. Bilateral versus single internal-thoracic-artery grafts at 10 years. N Engl J Med. 2019;380(5):437-446.
28. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. Circulation. 2022;145(3):e18-e114.
29. Hayward PAR, Gordon IR, Hare DL, et al. Long-term results of the RAPCO trials. Circulation. 2020;142(14):1330-1338.
30. Gaudino M, Bakaeen F, Davierwala P, Di Franco A, Fremes SE, et al. New Strategies for Surgical Myocardial Revascularization. Circulation. 2022;145(5):377-386.
31. Ohira S, Miyata H, Yamazaki S, et al. Total Arterial Revascularization Versus Conventional Coronary Artery Bypass Grafting in Patients With Multivessel Disease. Ann Thorac Surg. 2023;115(6):1428-1436.
32. El-Andari R, Bozso SJ, Moon MC, et al. Total Arterial Revascularization: A Review of Current Literature and Contemporary Outcomes. Semin Thorac Cardiovasc Surg. 2022;34(2):494-501.